< Back to all clusters
[HEALTH] · Italy · 13 sources

started · updated

Italy approves adrenaline nasal spray for anaphylaxis treatment

An adrenaline nasal spray has been approved for use in Italy as a life-saving alternative to traditional intramuscular injections for treating anaphylaxis. The device received authorization from the Italian Medicines Agency (AIFA), following prior approvals from the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).

Medical experts from the Italian Society of Allergology, Asthma, and Clinical Immunology (SIAAIC) noted that the spray addresses common barriers to emergency treatment, such as needle phobia and the social stigma of self-injection, which often lead to delays in care. Currently, the spray is indicated for individuals weighing over 30 kilograms. A pediatric formulation is expected to become available in the spring.

In Italy, approximately 10,000 cases of anaphylaxis are recorded annually, resulting in 60 deaths. Specialists highlighted that the nasal spray offers a longer shelf life of 30 months compared to the 18 months typical of standard auto-injectors, potentially improving accessibility and emergency preparedness.

Entities

European Medicines Agency · Food and Drug Administration · Italian Medicines Agency · Italy · SIAAIC

Claims

What the coverage asserts, and how many sources carry each claim.